Application of anti-VISTA antibody in drug combination

CN119032106APending Publication Date: 2024-11-26BIO THERA SOLUTIONS LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380032023.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-07
Filing Date
2023-04-07
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing treatment methods are difficult to effectively utilize VISTA antibodies to block its downstream immunosuppressive signaling pathways, thus lacking the ability of the immune system to effectively eliminate tumor cells in cancer treatment.

Method used

Provides a combination of an anti-VISTA antibody or antigen-binding fragment and other therapeutic agents, which specifically binds VISTA, blocks its immunosuppressive signaling pathway, and enhances the immune system's ability to clear tumor cells.

Benefits of technology

The combined use of anti-VISTA antibodies and other therapeutic agents significantly improved the anti-tumor functions of CD4+ and CD8+ T cells, prolonged the survival of mice, significantly inhibited tumor growth in tumor models, and improved the immune system's response to tumor cells. cleaning ability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000039_0000
    Figure 00000039_0000
  • Figure 00000039_0001
    Figure 00000039_0001
  • Figure 00000040_0000
    Figure 00000040_0000
Patent Text Reader

Abstract

The invention provides a composition containing an anti-VISTA antibody and application of the composition in drug combination. The composition comprises combined use of the anti-VISTA antibody and one or more other therapeutic agents. The composition and the application thereof can help an immune system to remove tumor cells, and can also be used for diagnosis and prognosis of tumors or cancers.
Need to check novelty before this filing date? Find Prior Art

Description

Application of anti-VISTA antibodies in combination therapy Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to a combination containing anti-VISTA antibodies and a combination thereof. Background Art

[0002] V domain immunoglobulin suppressor of T cell activation (VISTA), also known as PD-1H, B7-H5, DD1α, c10orf54, Gi24 or Dies1, is a type I transmembrane protein belonging to the immunoglobulin superfamily. The human VISTA gene is mainly expressed in hematopoietic cell lines and tissues rich in infiltrating leukocytes. In human peripheral blood mononuclear cells (PBMCs), CD14 + Monocytes, neutrophils, myeloid CD11c + DCs, CD4 + and CD8 + VISTA is expressed in T cells and other tissues. VISTA is highly conserved across species (>80%).

[0003] In the process of regulating immune responses, VISTA can act as a ligand to bind to the corepressor receptor (P-selectin glycoprotein ligand-1, PSGL-1) under acidic conditions, and can also act as a receptor-binding ligand (V-type immunoglobulin domain-containing protein 3, VSIG-3). Studies have shown that VISTA is expressed on the surface of naive T cells and is crucial for maintaining T cell quiescence and peripheral immune tolerance.

[0004] VISTA is involved in multiple diseases: In bladder cancer and melanoma models, VISTA monoclonal antibodies or VISTA gene knockout can significantly improve CD4 + and CD8 + T cell-mediated anti-tumor immunity; in the EAE (experimental allergic encephalomyelitis) model, VISTA monoclonal antibodies or VISTA gene knockout both aggravated disease progression; in an ovarian cancer model, VISTA monoclonal antibodies significantly prolonged the survival of mice with high VISTA expression. This suggests that VISTA is a potential target for cancer therapy. Therefore, therapeutic agents targeting VISTA will be beneficial for cancer treatment.

[0005] Summary of the Invention

[0006] The purpose of the present invention is to provide a new anti-VISTA antibody or antigen-binding fragment for use in combination with other therapeutic agents for the treatment of diseases. The VISTA antibody or antigen-binding fragment of the present invention can specifically bind to VISTA, block the immunosuppressive signaling pathway downstream of VISTA, and help the immune system eliminate tumor cells.

[0007] In one aspect, the present invention provides use of an anti-VISTA antibody or antigen-binding fragment in the preparation of a medicament for use in combination with one or more other therapeutic agents.

[0008] In another aspect, the present invention provides use of an anti-VISTA antibody or antigen-binding fragment and one or more other therapeutic agents in the preparation of a medicament for treating a disease.

[0009] In another aspect, the present invention provides use of an anti-VISTA antibody or antigen-binding fragment in combination with one or more other therapeutic agents in the treatment of a disease.

[0010] In another aspect, the present invention provides a method for treating a disease, such as a method for preventing, treating, or ameliorating a T cell dysfunction disorder, comprising administering an effective dose of an anti-VISTA antibody or antigen-binding fragment and one or more other therapeutic agents to a patient in need of treatment.

[0011] In some of the above embodiments, the anti-VISTA antibody or antigen-binding fragment and one or more other therapeutic agents are administered simultaneously. When the anti-VISTA antibody or antigen-binding fragment and one or more other therapeutic agents are administered simultaneously, the anti-VISTA antibody or antigen-binding fragment and one or more other therapeutic agents can be administered in the same or different manners, or made into a composition of an anti-VISTA antibody or antigen-binding fragment and one or more other therapeutic agents for administration. In some embodiments, the anti-VISTA antibody or antigen-binding fragment and one or more other therapeutic agents are administered separately. In some embodiments, the anti-VISTA antibody or antigen-binding fragment is administered before one or more other therapeutic agents. In some embodiments, the anti-VISTA antibody or antigen-binding fragment is administered after one or more other therapeutic agents.

[0012] In another aspect, the present invention provides a composition comprising an anti-VISTA antibody or antigen-binding fragment and one or more other therapeutic agents.

[0013] In another aspect, the present invention provides a method for preventing, treating, or ameliorating a T cell dysfunction disorder, comprising administering to a patient an effective dose of a composition comprising an anti-VISTA antibody or antigen-binding fragment and one or more other therapeutic agents.

[0014] In some embodiments, the additional therapeutic agent is an angiogenesis inhibitor, an anticancer agent, a targeted drug, or a therapeutic antibody.

[0015] In some embodiments, the anti-VISTA antibody or antigen-binding fragment specifically binds VISTA and comprises one or more CDRs, such as 1, 2, 3, 4, 5, or 6 CDRs, of the following:

[0016] (a) HCDR1 comprising or consisting of the amino acid sequence shown in SEQ ID NO: 1 or an amino acid sequence having a single substitution, deletion or insertion compared to SEQ ID NO: 1;

[0017] (b) HCDR2 comprising or consisting of the amino acid sequence shown in SEQ ID NO: 2 or an amino acid sequence having a single substitution, deletion or insertion compared to SEQ ID NO: 2;

[0018] (c) HCDR3 comprising or consisting of the amino acid sequence shown in SEQ ID NO: 3 or an amino acid sequence having a single substitution, deletion or insertion compared to SEQ ID NO: 3;

[0019] (d) LCDR1 comprising or consisting of the amino acid sequence shown in SEQ ID NO: 4 or an amino acid sequence having a single substitution, deletion or insertion compared to SEQ ID NO: 4;

[0020] (e) LCDR2, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 5 or an amino acid sequence having a single substitution, deletion or insertion compared to SEQ ID NO: 5;

[0021] (f) LCDR3 comprising or consisting of the amino acid sequence shown in SEQ ID NO: 6 or an amino acid sequence having a single substitution, deletion or insertion compared to SEQ ID NO: 6.

[0022] In some embodiments, the anti-VISTA antibody or antigen-binding fragment comprises:

[0023] (a) HCDR1 comprising or consisting of the amino acid sequence shown in SEQ ID NO: 1 or an amino acid sequence having a single substitution, deletion or insertion compared to SEQ ID NO: 1;

[0024] (b) HCDR2 comprising or consisting of the amino acid sequence shown in SEQ ID NO: 2 or an amino acid sequence having a single substitution, deletion or insertion compared to SEQ ID NO: 2; and

[0025] (c) HCDR3 comprising or consisting of the amino acid sequence shown in SEQ ID NO: 3 or an amino acid sequence having a single substitution, deletion or insertion compared to SEQ ID NO: 3.

[0026] In some embodiments, HCDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 1, HCDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 2, and HCDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO: 3.

[0027] In some embodiments, the anti-VISTA antibody or antigen-binding fragment comprises:

[0028] (d) LCDR1 comprising or consisting of the amino acid sequence shown in SEQ ID NO: 4 or an amino acid sequence having a single substitution, deletion or insertion compared to SEQ ID NO: 4;

[0029] (e) LCDR2 comprising or consisting of the amino acid sequence shown in SEQ ID NO: 5 or an amino acid sequence having a single substitution, deletion or insertion compared to SEQ ID NO: 5; and

[0030] (f) LCDR3 comprising or consisting of the amino acid sequence shown in SEQ ID NO: 6 or an amino acid sequence having a single substitution, deletion or insertion compared to SEQ ID NO: 6.

[0031] In some embodiments, LCDR1 comprises or consists of the amino acid sequence shown in SEQ ID NO:4, LCDR2 comprises or consists of the amino acid sequence shown in SEQ ID NO:5, and LCDR3 comprises or consists of the amino acid sequence shown in SEQ ID NO:6.

[0032] In one embodiment, the anti-VISTA antibody or antigen-binding fragment comprises HCDR1 as shown in SEQ ID NO: 1, HCDR2 as shown in SEQ ID NO: 2, HCDR3 as shown in SEQ ID NO: 3, LCDR1 as shown in SEQ ID NO: 4, LCDR2 as shown in SEQ ID NO: 5, and LCDR3 as shown in SEQ ID NO: 6.

[0033] In the above embodiments, the substitutions are conservative amino acid substitutions.

[0034] In some embodiments, the anti-VISTA antibody or antigen-binding fragment comprises a heavy chain variable region, which comprises the sequence shown in SEQ ID NO: 7 or 8, or a sequence having at least 80% identity with the sequence shown in SEQ ID NO: 7 or 8, or an amino acid sequence having one or more conservative amino acid substitutions compared to the sequence shown in SEQ ID NO: 7 or 8, or consists of the same.

[0035] In some embodiments, the anti-VISTA antibody or antigen-binding fragment comprises a light chain variable region, which comprises the sequence shown in SEQ ID NO: 9, a sequence having at least 80% identity to the sequence shown in SEQ ID NO: 9, or an amino acid sequence having one or more conservative amino acid substitutions compared to the sequence shown in SEQ ID NO: 9, or consists of the same.

[0036] In some embodiments, the anti-VISTA antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the sequence shown in SEQ ID NO:7, and the light chain variable region comprises the sequence shown in SEQ ID NO:9.

[0037] In some embodiments, the anti-VISTA antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the sequence shown in SEQ ID NO:8, and the light chain variable region comprises the sequence shown in SEQ ID NO:9.

[0038] In some embodiments, the anti-VISTA antibody or antigen-binding fragment further comprises a heavy chain constant region, a light chain constant region, an Fc region, or a combination thereof.

[0039] In some embodiments, the light chain constant region is a kappa or lambda chain constant region. In some preferred embodiments, the antibody or antigen-binding fragment thereof is of one of the IgG, IgM, IgA, IgE, or IgD isotypes; preferably, the isotype is IgG1, IgG2, IgG3, or IgG4. In some preferred embodiments, the antibody or antigen-binding fragment thereof is a murine antibody, a chimeric antibody, a humanized antibody, or a fully human antibody.

[0040] In some embodiments, Fc is a variant Fc region. In some embodiments, relative to the parent Fc region, the variant Fc region has one or more amino acid modifications, such as substitutions, deletions or insertions. In some embodiments, relative to the parent Fc region activity, the amino acid modifications in the Fc region change the effector function activity. In some embodiments, the variant Fc region can have altered (i.e., increased or decreased) antibody-dependent cellular cytotoxicity (ADCC), complement-mediated cytotoxicity (CDC), phagocytosis, opsonization or cell binding. In some embodiments, relative to the parent Fc region, the Fc region amino acid modifications can change the affinity of the variant Fc region to FcγR (Fcγ receptors). In some embodiments, the Fc region is derived from IgG1 or IgG4. In some embodiments, the Fc region mutation is an N297A mutation relative to the IgG1 subtype.

[0041] In some embodiments, the anti-VISTA antibody or antigen-binding fragment is an isolated antibody or antigen-binding fragment. In some embodiments, the antibody or antigen-binding fragment is scFv, Fab or F(ab)2.

[0042] In some embodiments, the anti-VISTA antibody or antigen-binding fragment comprises a heavy chain constant region, which comprises an amino acid sequence as shown in SEQ ID NO: 10, or a sequence having at least 80% identity with the sequence shown in SEQ ID NO: 10, or an amino acid sequence having one or more conservative amino acid substitutions compared to the sequence shown in SEQ ID NO: 10, or consists of the same; and / or

[0043] The anti-VISTA antibody or antigen-binding fragment comprises a light chain constant region, which comprises an amino acid sequence as shown in SEQ ID NO: 11, or a sequence having at least 80% identity to the sequence shown in SEQ ID NO: 11, or an amino acid sequence having one or more conservative amino acid substitutions compared to the sequence shown in SEQ ID NO: 11, or consists of the same.

[0044] In some embodiments, the anti-VISTA antibody or antigen-binding fragment comprises a heavy chain constant region and a light chain constant region, wherein the heavy chain constant region comprises an amino acid sequence as shown in SEQ ID NO: 10, and the light chain constant region comprises an amino acid sequence as shown in SEQ ID NO: 11.

[0045] In some embodiments, the anti-VISTA antibody or antigen-binding fragment comprises a heavy chain comprising, or consisting of, an amino acid sequence as set forth in SEQ ID NO: 12 or 13, a sequence having at least 80% identity to the sequence set forth in SEQ ID NO: 12 or 13, or an amino acid sequence having one or more conservative amino acid substitutions compared to the sequence set forth in SEQ ID NO: 12 or 13; and / or

[0046] The antibody or antigen-binding fragment comprises a light chain, which comprises an amino acid sequence as shown in SEQ ID NO: 14, a sequence having at least 80% identity with the sequence shown in SEQ ID NO: 14, or an amino acid sequence having one or more conservative amino acid substitutions compared to the sequence shown in SEQ ID NO: 14, or consists of the same.

[0047] In some embodiments, the heavy chain of the anti-VISTA antibody comprises the amino acid sequence as shown in SEQ ID NO: 12, and the light chain of the antibody comprises the amino acid sequence as shown in SEQ ID NO: 14.

[0048] In some embodiments, the heavy chain of the anti-VISTA antibody comprises the amino acid sequence as shown in SEQ ID NO: 13, and the light chain of the antibody comprises the amino acid sequence as shown in SEQ ID NO: 14.

[0049] In some embodiments, the anti-VISTA antibody or antigen-binding fragment is a monoclonal antibody (including a full-length monoclonal antibody), a polyclonal antibody, or a multispecific antibody or antigen-binding fragment (e.g., a bispecific antibody or antigen-binding fragment).

[0050] In some embodiments, the anti-VISTA antibody has two identical heavy chains and two identical light chains, and the Fc regions are paired to form disulfide bonds.

[0051] The anti-VISTA antibodies or antigen-binding fragments described in the present invention are disclosed in WO2022 / 206677.

[0052] In some embodiments, the other therapeutic agent is selected from antibodies or antigen-binding fragments or antibody-drug conjugates against the following targets: PD-L1, PD-1, CD3, such as anti-CD3 antibodies or anti-PD-L1 antibodies or antigen-binding fragments.

[0053] In some embodiments, the anti-PD-L1 antibody is Atezolizumab, Durvalumab, Avelumab, or Envafolimab.

[0054] In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment comprises HCDR1, HCDR2, and HCDR3 with amino acid sequences as shown in SEQ ID NOs: 24 to 26, respectively, and LCDR1, LCDR2, and LCDR3 with amino acid sequences as shown in SEQ ID NOs: 27 to 29, respectively.

[0055] In some embodiments, the anti-PD-L1 antibody or antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence as shown in positions 20-137 of SEQ ID NO: 19, or a sequence having at least 80% identity with positions 20-137 of SEQ ID NO: 19, or an amino acid sequence having one or more conservative amino acid substitutions with positions 20-137 of SEQ ID NO: 19; and

[0056] The anti-PD-L1 antibody or antigen-binding fragment comprises a light chain variable region, the amino acid sequence of which is shown as positions 23-129 of SEQ ID NO: 20, or a sequence having at least 80% identity with positions 23-129 of SEQ ID NO: 20, or an amino acid sequence having one or more conservative amino acid substitutions with positions 23-129 of SEQ ID NO: 20.

[0057] In some embodiments, the heavy chain amino acid sequence of the anti-PD-L1 antibody is as shown in positions 20-467 of SEQ ID NO: 19; the light chain amino acid sequence of the anti-PD-L1 antibody is as shown in positions 23-236 of SEQ ID NO: 20.

[0058] In some embodiments, the anti-VISTA antibody or antigen-binding fragment and the other therapeutic agent are administered separately. In some embodiments, the anti-VISTA antibody or antigen-binding fragment and the other therapeutic agent are administered simultaneously.

[0059] In some embodiments, the uses, methods and compositions of the present invention can be used to prevent, treat or improve T cell dysfunction disorders. In some embodiments, the T cell dysfunction disorders include tumors, cancers or infections.

[0060] In some embodiments, the anti-VISTA antibody is administered at a dose of 1-3000 mg per treatment cycle; alternatively, the anti-VISTA antibody is administered at a dose of 0.01-100 mg / kg of patient body weight per treatment cycle, or at a dose of 0.01 mg / kg-40 mg / kg of patient body weight per treatment cycle, or at a dose of 0.01 mg / kg-30 mg / kg of patient body weight per treatment cycle, or at a dose of 0.01 mg / kg-20 mg / kg of patient body weight per treatment cycle; alternatively, the anti-VISTA antibody is administered at a dose of 0.01-100 mg per treatment cycle. / kg patient body weight, or 0.1 mg / kg-40 mg / kg patient body weight, or 0.1 mg / kg-30 mg / kg patient body weight, or 0.1 mg / kg-20 mg / kg patient body weight; the anti-PD-L1 antibody is administered at a dose of 1-1500 mg in each treatment cycle; or, the anti-PD-L1 antibody is administered at a dose of 0.01 mg / kg to 100 mg / kg patient body weight, or 0.1 mg / kg to 20 mg / kg patient body weight in each cycle.

[0061] In some embodiments, therapeutically effective amounts of an anti-VISTA antibody or antigen-binding fragment and an anti-PD-L1 antibody or antigen-binding fragment are administered to a patient separately or simultaneously. The administration cycles of the anti-VISTA antibody or antigen-binding fragment and the anti-PD-L1 antibody or antigen-binding fragment can be the same or different.

[0062] In some embodiments, the T cell dysfunction disorder includes, but is not limited to, infections caused by bacteria, viruses, fungi, or protozoa, as well as cancer and tumors.

[0063] In some embodiments, the cancers and tumors include but are not limited to breast cancer, digestive tract cancer / gastrointestinal cancer, endocrine cancer, neuroendocrine cancer, eye cancer, genitourinary cancer, germ cell cancer, gynecological cancer, head and neck cancer, hematological cancer / blood cancer, musculoskeletal cancer, neurological cancer, respiratory cancer / thoracic cancer, bladder cancer, colon cancer, rectal cancer, colorectal cancer, lung cancer, endometrial cancer, kidney cancer, pancreatic cancer, liver cancer, stomach cancer, testicular cancer, esophageal cancer, prostate cancer, brain cancer, cervical cancer, ovarian cancer and thyroid cancer. In some embodiments, cancers and tumors include but are not limited to leukemia, melanoma and lymphoma. In some embodiments, leukemias include, but are not limited to, lymphocytic or myeloid leukemias (such as, for example, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid (myelocytic) leukemia (AML), chronic myeloid leukemia (CML)), hairy cell leukemia, T-cell prolymphocytic leukemia, large granular lymphocytic leukemia, or adult T-cell leukemia. In some embodiments, lymphomas include, but are not limited to, histiocytic lymphoma, follicular lymphoma, and Hodgkin's lymphoma. In some embodiments, infections include, but are not limited to, chronic infectious diseases such as HIV, HBV, HCV, and HSV.

[0064] The uses, methods and compositions of the present invention help the immune system to eliminate tumor cells and can be used to prevent, treat or improve T cell dysfunction disorders, such as cancer or tumors. BRIEF DESCRIPTION OF THE DRAWINGS

[0065] Figure 1 is an SDS-PAGE profile of the anti-VISTA antibody in Example 1 of the present invention; wherein, lane M represents a molecular marker marker, lane 1 represents antibody P48-6-K, lane 2 represents antibody P48-6-T, and lane 3 represents antibody VSTB112.

[0066] FIG2 shows that anti-VISTA antibodies block the binding of VSIG-3 to VISTA.

[0067] Figure 3 shows that anti-VISTA antibodies promote T cell proliferation; in the figure, ** indicates p < 0.01, **** indicates p < 0.0001.

[0068] FIG4A shows the effect of the antibody on tumor volume; FIG4B shows the effect of the antibody on tumor weight; in the figure, * indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, and ns indicates no significant difference.

[0069] FIG5 shows the effect of antibodies on mouse body weight. DETAILED DESCRIPTION

[0070] the term

[0071] Unless otherwise stated, each of the following terms shall have the meaning set forth below.

[0072] definition

[0073] It should be noted that the term "a" entity refers to one or more of that entity, e.g., "an antibody" should be understood as one or more antibodies, and thus, the terms "a" (or "an"), "one or more" and "at least one" can be used interchangeably herein.

[0074] The term "polypeptide" is intended to encompass the singular "polypeptide" as well as the plural "polypeptides" and refers to a molecule composed of amino acid monomers linearly linked by amide bonds (also known as peptide bonds). The term "polypeptide" refers to any single or multiple chains of two or more amino acids and does not refer to the specific length of the product. Thus, the definition of "polypeptide" includes peptides, dipeptides, tripeptides, oligopeptides, "proteins," "amino acid chains," or any other terms used to refer to two or more amino acid chains, and the term "polypeptide" may be used in place of or interchangeably with any of the above terms. The term "polypeptide" is also intended to refer to products of polypeptides that have been modified after expression, including but not limited to glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting / blocking groups, proteolytic cleavage, or non-naturally occurring amino acid modifications. A polypeptide may be derived from a natural biological source or produced by recombinant technology, but it need not be translated from a specified nucleic acid sequence and may be produced by any means, including chemical synthesis.

[0075] "Amino acids" refer to organic compounds containing both amino and carboxyl groups, such as α-amino acids, which can be encoded by nucleic acids directly or in the form of precursors. Individual amino acids are encoded by nucleic acids consisting of three nucleotides (so-called codons or base triplets). Each amino acid is encoded by at least one codon. The fact that the same amino acid is encoded by different codons is called "degeneracy of the genetic code." Amino acids include natural amino acids and unnatural amino acids. Natural amino acids include alanine (three-letter code: ala, one-letter code: A), arginine (arg, R), asparagine (asn, N), aspartic acid (asp, D), cysteine ​​(cys, C), glutamine (gln, Q), glutamic acid (glu, E), glycine (gly, G), histidine (his, H), isoleucine (ile, I), leucine (leu, L), lysine (lys, K), methionine (met, M), phenylalanine (phe, F), proline (pro, P), serine (ser, S), threonine (thr, T), tryptophan (trp, W), tyrosine (tyr, Y) and valine (val, V).

[0076] A "conservative amino acid substitution" is one in which an amino acid residue is replaced with another amino acid residue that has a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). In general, conservative amino acid substitutions are unlikely to substantially alter the functional properties of a protein. Examples of amino acid classes with chemically similar side chains include: 1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; 2) aliphatic hydroxyl side chains: serine and threonine; 3) amide-containing side chains: asparagine and glutamine; 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; 5) basic side chains: lysine, arginine, and histidine; and 6) acidic side chains: aspartic acid and glutamic acid.

[0077] The number of amino acids in “conservative amino acid substitutions of VL, VH” is about 1, about 2, about 3, about 4, about 5, about 6, about 8, about 9, about 10, about 11, about 13, about 14, about 15 conservative amino acid substitutions, or a range between any two of these values ​​(including endpoints) or any value therein. The number of amino acids in the “conservative amino acid substitution in the heavy chain constant region, light chain constant region, heavy chain or light chain” is about 1, about 2, about 3, about 4, about 5, about 6, about 8, about 9, about 10, about 11, about 13, about 14, about 15, about 18, about 19, about 22, about 24, about 25, about 29, about 31, about 35, about 38, about 41, about 45 conservative amino acid substitutions, or a range between any two of these values ​​(including endpoints) or any value therein.

[0078] As used herein with respect to cells, nucleic acids, polypeptides, antibodies, and the like, the term "isolated" refers to a molecule that has been separated from one or more of the other components of a cell's natural environment, such as DNA or RNA. The term "isolated" also refers to a nucleic acid or peptide that is substantially free of cellular material, viral material, or cell culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. Furthermore, "isolated nucleic acid" is intended to include nucleic acid fragments that do not exist in their natural state and do not exist in their natural state. The term "isolated" is also used herein to refer to cells or polypeptides that have been separated from other cellular proteins or tissues. Isolated polypeptides are intended to include purified and recombinant polypeptides. Isolated polypeptides, antibodies, and the like are typically prepared by at least one purification step. In some embodiments, the purity of an isolated nucleic acid, polypeptide, antibody, and the like is at least about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 99%, or a range (including the endpoints) between any two of these values, or any value therein.

[0079] The term "recombinant" in reference to a polypeptide or polynucleotide refers to a form of the polypeptide or polynucleotide that does not occur in nature, and by way of non-limiting example, can be produced by combination with a polynucleotide or polypeptide that does not normally exist.

[0080] "Homology" or "identity" or "similarity" refers to the sequence similarity between two peptides or two nucleic acid molecules. Homology can be determined by comparing alignable positions in each sequence. When a position in the compared sequences is occupied by the same base or amino acid, the molecules are homologous at that position. The degree of homology between the sequences is a function of the number of matching or homologous positions shared by the sequences.

[0081] "At least 80% identity" means about 80% identity, about 81% identity, about 82% identity, about 83% identity, about 85% identity, about 86% identity, about 87% identity, about 88% identity, about 90% identity, about 91% identity, about 92% identity, about 94% identity, about 95% identity, about 98% identity, about 99% identity, or a range between any two of these values ​​(including the endpoints) or any value therein.

[0082] A polynucleotide or polynucleotide sequence (or polypeptide or antibody sequence) having a certain percentage (e.g., 90%, 95%, 98% or 99%) of "identity or sequence identity" to another sequence means that when the sequences are aligned, that percentage of bases (or amino acids) in the two sequences being compared are the same. The alignment and percent identity or sequence identity can be determined visually or using software programs known in the art, such as those described in Ausubel et al., eds. (2007), in Current Protocols in Molecular Biology. Preferably, the alignment is performed using the default parameters. One such alignment program is BLAST using default parameters, such as BLASTN and BLASTP, both of which use the following default parameters: Geneticcode=standard; filter=none; strand=both; cutoff=60; expectation=10; Matrix=BLOSUM62; Descriptions=50 sequences; sortby=HIGHSCORE; Databases=non-redundant; GenBank+EMBL+DDBJ+PDB+GenBankCDStranslations+SwissProtein+SPupdate+PIR. Biologically equivalent polynucleotides are polynucleotides that have the above specified percentage identities and encode polypeptides having the same or similar biological activity.

[0083] The term "encoding" when applied to a polynucleotide refers to a polynucleotide that is said to "encode" a polypeptide and that, in its native state or when manipulated by methods well known to those skilled in the art, can produce the polypeptide and / or its fragments via transcription and / or translation.

[0084] The antibodies and antigen-binding fragments disclosed in the present invention include, but are not limited to, polyclonal antibodies, monoclonal antibodies, multispecific antibodies, fully human antibodies, humanized antibodies, primatized antibodies, chimeric antibodies, single-chain antibodies, epitope-binding fragments (e.g., Fab, Fab' and F(ab')2), and single-chain Fvs (scFv).

[0085] "Antibody" and "antigen-binding fragment" refer to polypeptides or polypeptide complexes that specifically recognize and bind to an antigen. An antibody can be a complete antibody, any antigen-binding fragment thereof, or a single chain thereof. Therefore, the term "antibody" includes any protein or peptide that contains at least a portion of an immunoglobulin molecule with biological activity that binds to an antigen. Antibodies and antigen-binding fragments include, but are not limited to, the complementarity determining regions (CDRs) of a heavy chain or light chain or its ligand-binding portion, the heavy chain variable region (VH), the light chain variable region (VL), the heavy chain constant region (CH), the light chain constant region (CL), the framework regions (FRs), or any portion thereof, or at least a portion of a binding protein. CDR regions include the CDR regions (LCDR1-3) of the light chain and the CDR regions (HCDR1-3) of the heavy chain. Antibodies and antigen-binding fragments can specifically recognize and bind to polypeptides or polypeptide complexes of one or more (e.g., two) antigens. Antibodies or antigen-binding fragments that specifically recognize and bind to multiple (e.g., two) antigens can be referred to as multispecific (e.g., bispecific) antibodies or antigen-binding fragments.

[0086] The term "antibody fragment" or "antigen-binding fragment" refers to a portion of an antibody. Antibody fragments of the present invention may be structured in forms similar to monospecific antibody fragments such as F(ab')2, F(ab)2, Fab', Fab, Fv, and scFv. Regardless of their structure, antibody fragments bind to the same antigen recognized by the intact antibody. The term "antibody fragment" includes aptamers, Spiegelmers, and diabodies. The term "antigen-binding fragment" also includes any synthetic or genetically engineered protein that functions as an antibody by binding to a specific antigen to form a complex.

[0087] "Single-chain variable fragment" or "scFv" refers to a fusion protein of the variable regions of the heavy chain (VH) and light chain (VL) of an immunoglobulin. In some aspects, these regions are connected with a short linker peptide of 10 to about 25 amino acids. The linker can be rich in glycine to increase flexibility, as well as rich in serine or threonine to increase solubility, and can connect the N-terminus of VH to the C-terminus of VL, or vice versa. Although the protein has the constant region removed and the linker introduced, it retains the specificity of the original immunoglobulin. scFv molecules are generally known in the art and are described, for example, in U.S. Patent No. 5,892,019.

[0088] The term "antibody" includes a wide variety of polypeptides that can be distinguished biochemically. It will be understood by those skilled in the art that the categories of heavy chains include gamma, mu, alpha, delta or epsilon (γ, μ, α, δ, ε), with some subclasses (e.g., γ1-γ4) also included. The nature of this chain determines the "class" of the antibody, which is IgG, IgM, IgA, IgD or IgE, respectively. Immunoglobulin subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgG5, etc., have been fully characterized and the functional specificity conferred is also known. All immunoglobulin classes are within the scope of protection disclosed herein. In some embodiments, the immunoglobulin molecule is an IgG class.

[0089] Light chains can be divided into kappa (κ) or lambda (λ). Each heavy chain can be combined with a κ or λ light chain. Generally speaking, when immunoglobulins are produced by hybridomas, B cells or genetically engineered host cells, their light chains and heavy chains are bound by covalent bonds, and the "tail" parts of the two heavy chains are bound by covalent disulfide bonds or non-covalent bonds. In the heavy chain, the amino acid sequence extends from the N-terminus of the forked end of the Y configuration to the C-terminus at the bottom of each chain. The variable region of the immunoglobulin κ light chain is Vκ; the variable region of the immunoglobulin λ light chain is V λ .

[0090] Both light and heavy chains are divided into regions of structural and functional homology. The terms "constant" and "variable" are used in accordance with the function. The light chain variable region (VL) and the heavy chain variable region (VH) determine, in part, antigen recognition and specificity. The constant regions of the light and heavy chains confer important biological properties such as secretion, transplacental movement, Fc receptor binding, complement fixation, etc. By convention, the numbering of the constant regions increases as they become more distal to the antigen binding site or amino terminus of the antibody. The N-terminal portion is the variable region and the C-terminal portion is the constant region; the CH3 and CL domains actually contain the carboxyl termini of the heavy and light chains, respectively.

[0091] In naturally occurring antibodies, the six "complementarity determining regions" or "CDRs" present in each antigen binding domain are short, non-contiguous amino acid sequences that form the antigen binding domain, assuming the antibody assumes its three-dimensional configuration in an aqueous environment, and that specifically bind to the antigen. The remaining amino acids in the antigen binding domain, referred to as the "framework" region, exhibit less intermolecular variability. The framework regions largely adopt a β-sheet conformation, with the CDRs forming loops connected thereto, or in some cases forming part of the β-sheet structure. Thus, the framework regions, by forming a scaffold, position the CDRs in the correct orientation through interchain non-covalent interactions. The antigen binding domain, with its specifically positioned CDRs, forms a surface complementary to an epitope on the antigen, which promotes non-covalent binding between the antibody and its antigenic epitope. For a given heavy or light chain variable region, one of ordinary skill in the art can identify the amino acids comprising the CDRs and framework regions by known methods (see Kabat, E., et al., US Department of Health and Human Services, Sequences of Proteins of Immunological Interest, (1983) and Chothia and Lesk, J. Mol. Biol., 196:901-917 (1987)).

[0092] In the case where there are two or more definitions of a term used and / or accepted in the art, the definition of the term used herein includes all of these meanings unless explicitly stated to the contrary. A specific example is the use of the term "complementarity determining region" ("CDR") to describe the non-continuous antigen binding sites found in the variable regions of heavy and light chain polypeptides. This particular region is described in Kabat et al., US Pat. of Health and Human Services, Sequences of Proteins of Immunological Interest (1983) and Chothia et al., J. Mol. Biol. 196: 901-917 (1987), which are incorporated herein by reference in their entirety.

[0093] The CDRs defined according to Kabat and Chothia include overlapping or subsets of amino acid residues when compared to each other. Nevertheless, the application of either definition to refer to the CDRs of an antibody or its variants is within the scope of the present invention. The exact residue numbering comprising a particular CDR will vary depending on the sequence and size of the CDR. Those skilled in the art can generally determine which specific residues a CDR comprises based on the variable region amino acid sequence of an antibody.

[0094] Kabat et al. also defined a numbering system applicable to the variable region sequence of any antibody. Those skilled in the art can apply this "Kabat numbering" system to any variable region sequence independently of experimental data other than the sequence itself. "Kabat numbering" refers to the numbering system proposed by Kabat et al., U.S. Department of Health and Human Services in "Sequence of Proteins of Immunological Interest" (1983). Antibodies can also use the EU or Chothia numbering system.

[0095] The antibodies disclosed herein can be derived from any animal, including birds and mammals. Preferably, the antibodies are human, mouse, donkey, rabbit, goat, camel, llama, horse, or chicken. In another embodiment, the variable region can be of condricthoid origin (e.g., from shark).

[0096] The "heavy chain constant region" includes at least one of a CH1 domain, a hinge (e.g., upper, middle, and / or lower hinge region) domain, a CH2 domain, a CH3 domain, or a variant or fragment. The heavy chain constant region of an antibody can be derived from different immunoglobulin molecules. For example, the heavy chain constant region of a polypeptide can include a CH1 domain derived from an IgG1 molecule and a hinge region derived from an IgG3 molecule. In another embodiment, the heavy chain constant region can include a hinge region that is partially derived from an IgG1 molecule and partially derived from an IgG3 molecule. In another embodiment, a portion of the heavy chain can include a chimeric hinge region that is partially derived from an IgG1 molecule and partially derived from an IgG4 molecule.

[0097] A "light chain constant region" comprises a portion of the amino acid sequence from an antibody light chain. Preferably, the light chain constant region comprises at least one of a constant kappa domain or a constant lambda domain. A "light chain-heavy chain pair" refers to a collection of light and heavy chains that can form a dimer via disulfide bonds between the light chain CL domain and the heavy chain CH1 domain. These four chains are connected by disulfide bonds in a "Y" configuration, with the light chain beginning at the mouth of the "Y" and continuing through the variable region to surround the heavy chain.

[0098] The "VH domain" includes the amino-terminal variable domain of the immunoglobulin heavy chain, and the "CH1 domain" includes the first (most amino-terminal) constant region of the immunoglobulin heavy chain. In the complete natural IgG molecule, N297 in each of the two CH2 domains is connected to a branched carbohydrate chain. The CH3 domain extends from the CH2 domain to the C-terminus of the IgG molecule and contains approximately 108 residues. The "hinge region" includes the partial heavy chain region connecting the CH1 domain and the CH2 domain. The hinge region contains about 25 residues and is tough, so that the two N-terminal antigen-binding regions can move independently. The hinge region can be subdivided into three different domains: upper, middle and lower hinge domains (Roux et al., J. Immunol 161:4083 (1998)).

[0099] In some embodiments, the antibody or antigen binding fragment comprises an amino acid sequence with one or more modifying groups. For example, the antibody or antigen binding fragment can include a tough linker sequence, or can be modified to add a functional group (such as PEG, a drug, a toxin, or a label). Antibodies and antigen binding fragments include modified derivatives, i.e., modified by the covalent connection of any type of molecule to the antibody or antigen binding fragment, wherein the covalent connection does not prevent the antibody or antigen binding fragment from binding to the epitope. Including but not limited to the following examples, the antibody or antigen binding fragment can be glycosylated, acetylated, pegylated, phosphorylated, amidated, derivatized by known protection / blocking groups, proteolytic cleavage, connected to cell ligands or other proteins, etc. Any modification in numerous chemical modifications can be carried out by existing technology, including but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Antibodies or antigen binding fragments can be conjugated with therapeutic agents, prodrugs, peptides, proteins, enzymes, viruses, lipids, biological response modifiers, pharmaceutical agents, or PEG. Antibodies or antigen binding fragments can be detectably labeled by coupling them to chemiluminescent compounds. The presence of the chemiluminescent labeled antibody or antigen-binding fragment is then determined by detecting the luminescence that occurs during the chemical reaction. Examples of chemiluminescent labeling compounds include luminol, isoluminol, aromatic acridinium esters, imidazoles, acridinium salts, and oxalate esters.

[0100] A "disulfide bond" refers to a covalent bond formed between two sulfur atoms. A thiol group of a cysteine ​​can form a disulfide bond, or bridge, with a second thiol group. In most naturally occurring IgG molecules, the CH1 and CL regions are linked by a disulfide bond.

[0101] A "chimeric antibody" refers to any antibody whose variable region is obtained or derived from a first species and whose constant region (which may be complete, partial, or modified) is derived from a second species. In certain embodiments, the variable region is from a non-human source (e.g., mouse or primate) and the constant region is from a human source.

[0102] "Specific binding" or "specific for..." generally refers to the formation of a relatively stable complex between an antibody or antigen-binding fragment and a specific antigen through the complementary binding of its antigen-binding domain to the epitope. "Specificity" can be expressed in terms of the relative affinity of the antibody or antigen-binding fragment for binding to a specific antigen or epitope. For example, if antibody "A" has a greater relative affinity than antibody "B" for the same antigen, it can be considered that antibody "A" has a higher specificity for the antigen than antibody "B". Specific binding can be expressed in terms of the equilibrium dissociation constant (K D ) to describe, the smaller K D Means relatively tight binding. Methods for determining whether two molecules specifically bind are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, biofilm optical interferometry, etc. An antibody that "specifically binds" to antigen a includes an equilibrium dissociation constant K of 1. D An antibody of less than or equal to about 100 nM, less than or equal to about 10 nM, less than or equal to about 5 nM, less than or equal to about 1 nM, or less than or equal to about 0.5 nM.

[0103] "Treatment" refers to both therapeutic treatment and prophylactic or preventative measures, the purpose of which is to prevent, slow, ameliorate or halt an undesirable physiological change or disorder, such as the progression of a disease, including but not limited to the following results, whether detectable or undetectable, relief of symptoms, reduction in the severity of the disease, stabilization of the disease state (i.e., no worsening), delay or slowing of disease progression, improvement, alleviation, reduction or elimination of the disease state (whether partial or complete), prolongation of life expectancy compared to that expected in the absence of treatment, etc. Patients in need of treatment include those already suffering from the disease or disorder, those susceptible to the disease or disorder, or those in need of prevention of the disease or disorder, and those who can or are expected to benefit from the administration of the antibodies or pharmaceutical compositions disclosed herein for detection, diagnostic procedures and / or treatment.

[0104] "Patient" refers to any mammal in need of diagnosis, prognosis or treatment, including humans, dogs, cats, rabbits, mice, horses, cows, etc.

[0105] Anti-VISTA antibodies

[0106] The present invention provides antibodies or antigen-binding fragments thereof with high affinity for the VISTA protein. The antibodies or antigen-binding fragments of the present invention exhibit effective binding activity and biological activity and can be used for therapeutic and diagnostic purposes. For example, these antibodies or antigen-binding fragments can effectively block inhibitory immune checkpoints and activate lymphocytes to release cytokines, and are used to treat various types of cancers, tumors, infections, and other related diseases.

[0107] In some embodiments, the heavy chain of the antibody comprises the amino acid sequence shown in SEQ ID NO: 12, and the light chain of the antibody comprises the amino acid sequence shown in SEQ ID NO: 14. In some embodiments, the heavy chain of the antigen-binding fragment comprises the amino acid sequence of SEQ ID NO: 12 excluding Fc, and the light chain of the antigen-binding fragment comprises the amino acid sequence shown in SEQ ID NO: 14.

[0108] In some embodiments, the heavy chain of the antibody comprises the amino acid sequence shown in SEQ ID NO: 13, and the light chain of the antibody comprises the amino acid sequence shown in SEQ ID NO: 14. In some embodiments, the heavy chain of the antigen-binding fragment comprises the amino acid sequence of SEQ ID NO: 13 excluding Fc, and the light chain of the antigen-binding fragment comprises the amino acid sequence shown in SEQ ID NO: 14.

[0109] In some embodiments, an antibody of the invention contains two sequence-identical heavy chains (or heavy chain fragments) and two sequence-identical light chains (or light chain fragments).

[0110] It will also be understood by those skilled in the art that the sequences of the antibodies or antigen-binding fragments disclosed herein can be substituted, and the amino acid sequence after substitution is different from the naturally occurring amino acid sequence of the antibody. For example, the substituted amino acid sequence can be similar to the starting sequence, such as having a certain ratio of identity with the starting sequence, such as about 80%, about 85%, about 90%, about 95%, about 98%, about 99% identity with the starting sequence, or a range between any two of these values ​​(including the endpoints) or any value therein.

[0111] Methods for preparing antibodies

[0112] In certain embodiments, the prepared antibodies do not cause a harmful immune response in the animal to be treated (e.g., a human). In some embodiments, the antibodies, antigen-binding fragments, or derivatives disclosed herein are modified using techniques recognized in the art to reduce their immunogenicity. For example, antibodies can be humanized, primatized, deimmunized, or chimeric antibodies can be prepared. These types of antibodies are derived from non-human antibodies, typically murine or primate antibodies, which retain or substantially retain the antigen-binding properties of the parent antibody but have lower immunogenicity in humans. This can be achieved by a variety of methods, including (a) transplanting the entire non-human variable region into a human constant region to produce a chimeric antibody; (b) transplanting at least a portion of one or more non-human complementary determining regions (CDRs) into a human framework and constant region, retaining or not retaining key framework residues; or (c) transplanting the entire non-human variable region, but "hiding" them by replacing surface residues with human-like portions. Typically, the framework residues in the human framework region will be replaced by corresponding residues from the CDR donor antibody, such as residues that can improve antigen binding. These framework replacements can be identified by methods well known in the art, such as by modeling the interactions of CDR and framework residues to identify framework residues that are important for antigen binding and by sequence alignment to identify unusual framework residues at specific positions (see U.S. Pat. No. 5,585,089; Riechmann et al., Nature 332:323 (1988); the entire contents of which are incorporated herein by reference). Antibodies can be humanized using a variety of techniques known in the art, such as CDR grafting (EP 239,400; WO 91 / 09967; U.S. Pat. Nos. 5,225,539, 5,530,101, and 5,585,089), repair or resurfacing (EP 592,106; EP 519,596; Padlan, et al., Molecular Immunology 28(4 / 5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska, et al., Proc. Natl. Sci. USA 91:969-973 (1994)), and chain shuffling (U.S. Pat. No. 5,565,332), the entire contents of which are incorporated herein by reference.

[0113] Deimmunization can also be used to reduce the immunogenicity of antibodies. In the present invention, the term "deimmunization" includes changing antibodies to modify T cell epitopes (see, for example, WO / 9852976A1 and WO / 0034317A2). For example, the heavy chain variable region sequence and light chain variable region sequence from the starting antibody are analyzed, and a human T cell epitope "map" from each variable region is generated, showing the position of the epitope relative to the complementary determining region (CDRs) and other key residues in the sequence. A single T cell epitope from the T cell epitope map is analyzed to identify optional amino acid substitutions with a lower risk of changing the antibody activity. A series of optional heavy chain variable region sequences and light chain variable region sequences containing amino acid substitution combinations are designed, and these sequences are subsequently incorporated into a series of binding polypeptides. The genes for the complete heavy and light chains containing the modified variable regions and human constant regions are then cloned into expression vectors, and the plasmids are subsequently transferred into cell lines to produce complete antibodies. The antibodies are then compared in appropriate biochemical and biological experiments to identify the best antibodies.

[0114] The binding specificity of the antibodies or antigen-binding fragments disclosed herein can be detected by in vitro assays, such as immunoprecipitation, radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA).

[0115] The preparation of scFv can refer to the technology of producing single-chain units (U.S. Patent 4,694,778; Bird, Science 242:423-442 (1988), Huston et al., Proc. Natl. Acad. Sci. USA 55:5879-5883 (1988) and Ward et al., Nature 334:544-554 (1989) and Nie et al., Antibody Therapeutics 3 (1): 18-62 (2020)). The heavy chain and light chain fragments of the Fv region are bridged by amino acids to form a single-chain unit to produce a single-chain fusion peptide. The technology of assembling functional Fv fragments in Escherichia coli can also be used (Skerra et al., Science 242: 1038-1041 (1988)).

[0116] Examples of techniques that can be used to produce single-chain Fv (scFv) and antibodies include those described in U.S. Patents 4,946,778 and 5,258,498, as well as Huston et al., Methods in Enzymology 203:46-88 (1991), Shu et al., Proc. Natl. Sci. USA 90:1995-1999 (1993), and Skerra et al., Science 240:1038-1040 (1988). For certain uses, including in vivo use of antibodies and in vitro detection experiments, chimeric, humanized, or fully human antibodies can be used. Chimeric antibodies are a class of molecules in which different portions of an antibody are derived from different animal species, such as antibodies having the variable regions of a mouse monoclonal antibody and the constant regions of a human immunoglobulin. Methods for producing chimeric antibodies are known in the art, see Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Gillies et al., J. Immunol. Methods 125:191-202 (1989); Neuberger et al., Nature 372:604-608 (1984); Takeda et al., Nature 314:452-454 (1985); and U.S. Patents 5,807,715, 4,816,567 and 4,816,397, the entire contents of which are incorporated herein by reference.

[0117] In addition, another efficient method for producing recombinant antibodies is disclosed in Newman, Biotechnology 10:1455-1460 (1992), in particular, this technology can produce primate antibodies containing monkey variable region and human constant region sequences, the entire content of which is incorporated herein by reference. In addition, this technology is also mentioned in U.S. Patents 5,658,570, 5,693,780 and 5,756,096, the entire content of each patent is incorporated herein by reference.

[0118] Antibodies can be prepared by various methods known in the art, including phage display methods using antibody libraries derived from immunoglobulin sequences. Reference may also be made to U.S. Patents 4,444,887 and 4,716,111, and PCT Publications WO 98 / 46645, WO 98 / 50433, WO 98 / 24893, WO 98 / 16654, WO 96 / 34096, WO 96 / 33735, and WO 91 / 10741, the entire contents of each of which are incorporated herein by reference.

[0119] In another embodiment, using conventional methods (such as using oligonucleotide probes that can specifically bind to the genes encoding mouse antibody heavy and light chains), the DNA encoding the desired monoclonal antibody can be isolated and sequenced. Isolation and subcloning of hybridoma cells can be used as the source of this type of DNA. Once isolated, DNA can be placed in an expression vector and then transfected into prokaryotic or eukaryotic host cells such as Escherichia coli cells, monkey COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not produce other immunoglobulins. Isolation of DNA (which can be synthetic as described herein) can also be used to prepare the sequence of the constant and variable regions of antibodies, as described in U.S. Patent No. 5,658,570, the entire contents of which are incorporated herein by reference. The method extracts RNA from selected cells and is converted into cDNA, which is then amplified by PCR technology using Ig-specific primers. Suitable probes for this purpose are also mentioned in U.S. Patent No. 5,658,570.

[0120] In addition, using conventional recombinant DNA technology, one or more CDRs of the antibodies of the present invention can be inserted into the framework region, for example, into the human framework region to construct a humanized non-fully human antibody. The framework region can be a naturally occurring or shared framework region, preferably a human framework region (see Chothia et al., J. Mol. Biol. 278: 457-479 (1998), which lists a series of human framework regions). Some polynucleotides can encode antibodies that specifically bind to at least one epitope of the target antigen produced by the combination of framework regions and CDRs. One or more amino acid substitutions can be made within the framework region, and amino acid substitutions that can improve the binding of the antibody to its antigen can be selected. In addition, this method can be used to replace or delete cysteine ​​residues in one or more variable regions involved in the formation of interchain disulfide bonds, thereby producing antibody molecules lacking one or more interchain disulfide bonds. Other changes to polynucleotides within the scope of the art are also encompassed in the present invention.

[0121] Antibodies can be prepared using conventional recombinant DNA techniques. Antibody-producing vectors and cell lines can be selected, constructed, and cultured using techniques well known to those skilled in the art. These techniques are described in various laboratory manuals and major publications, such as Recombinant DNA Technology for Production of Protein Therapeutics in Cultured Mammalian Cells, DL Hacker, FMWurm, in Reference Module in Life Sciences, 2017, the entire contents of which, including supplementary content, are incorporated by reference in their entirety.

[0122] In some embodiments, DNA encoding the antibody can be designed and synthesized according to conventional methods based on the antibody amino acid sequence described herein, inserted into an expression vector, and then transfected into host cells. The transfected host cells are then cultured in culture medium to produce monoclonal antibodies. In some embodiments, the antibody expression vector comprises at least one promoter element, an antibody coding sequence, a transcription termination signal, and a polyA tail. Other elements include enhancers, Kozak sequences, and donor and acceptor sites for RNA splicing on either side of the inserted sequence. Efficient transcription can be achieved using the early and late promoters of SV40, and the early promoters of long terminal repeats from retroviruses such as RSV, HTLV1, HIV, and cytomegalovirus. Other cellular promoters, such as the actin promoter, can also be used. Suitable expression vectors may include pIRES1neo, pRetro-Off, pRetro-On, PLXSN, or pLNCX, pcDNA3.1 (+ / -), pcDNA / Zeo (+ / -), pcDNA3.1 / Hygro (+ / -), PSVL, PMSG, pRSVcat, pSV2dhfr, pBC12MI, and pCS2, etc. Commonly used mammalian cells include HEK293 cells, Cos1 cells, Cos7 cells, CV1 cells, mouse L cells, and CHO cells, etc.

[0123] In some embodiments, the inserted gene fragment needs to contain a selection marker. Common selection markers include dihydrofolate reductase, glutamine synthetase, neomycin resistance, hygromycin resistance, and other selection markers to facilitate the screening and isolation of successfully transfected cells. The constructed plasmid is transfected into host cells lacking these genes. After culture in a selective medium, the successfully transfected cells grow in large numbers and produce the desired target protein.

[0124] In addition, standard techniques known to those skilled in the art can be used to introduce mutations into the nucleotide sequences encoding the antibodies of the present invention, including but not limited to site-directed mutagenesis and PCR-mediated mutagenesis that result in amino acid substitutions. Variants (including derivatives) encode less than 50 amino acid substitutions, less than 40 amino acid replacements, less than 30 amino acid replacements, less than 25 amino acid replacements, less than 20 amino acid replacements, less than 15 amino acid replacements, less than 10 amino acid replacements, less than 5 amino acid replacements, less than 4 amino acid replacements, less than 3 amino acid replacements, or less than 2 amino acid replacements relative to the original heavy chain variable region and light chain variable region. Alternatively, mutations can be introduced randomly along all or part of the coding sequence, for example, by saturation mutagenesis, and the resulting mutants can be screened for biological activity to identify mutants that retain activity.

[0125] Treatment

[0126] The present invention also provides methods of treatment and uses. In some embodiments, there is provided a method for treating or improving various types of cancers, tumors or infections and other related diseases, the method comprising administering an effective dose of an anti-VISTA antibody or antigen-binding fragment and one or more other therapeutic agents to a patient in need. In some embodiments, there is provided an application of an anti-VISTA antibody or antigen-binding fragment in combination with one or more other therapeutic agents for treating or improving cancer, tumors or infections and other related diseases. In some embodiments, there is provided an application of the anti-VISTA antibody or antigen-binding fragment in the preparation of a drug for treating or improving cancer, tumors or infections and other related diseases in combination with one or more other therapeutic agents. In some embodiments, there is provided an application of the anti-VISTA antibody or antigen-binding fragment in the preparation of a drug for treating or improving cancer, tumors or infections and other related diseases. In some embodiments, the other therapeutic agents are as described herein.

[0127] The specific dosage and treatment regimen for any particular patient will depend on various factors, including the specific antibody or derivative used, the patient's age and weight, general health, sex and diet, as well as the time of administration, frequency of excretion, drug combination, and the severity of the specific disease being treated. These factors are judged by medical care personnel included within the scope of those of ordinary skill in the art. The dosage will also depend on the individual patient to be treated, the route of administration, the type of formulation, the characteristics of the compound used, the severity of the disease, and the desired effect. The dosage used can be determined by pharmacological and pharmacokinetic principles well known in the art. In some embodiments, the anti-VISTA antibody is administered to the patient at a dosage of 0.01 mg / kg to 100 mg / kg of patient body weight each time. In some embodiments, the dosage is administered once every 1 week, 2 weeks, 3 weeks, or monthly. In some embodiments, the dosage of the antibody is 0.1-20 mg / kg administered each time.

[0128] In some embodiments, the anti-VISTA antibody or antigen-binding fragment and one or more other therapeutic agents are administered simultaneously. When the anti-VISTA antibody or antigen-binding fragment and one or more other therapeutic agents are administered simultaneously, the anti-VISTA antibody or antigen-binding fragment and one or more other therapeutic agents can be administered in the same or different manners, or made into a composition of the anti-VISTA antibody or antigen-binding fragment and one or more other therapeutic agents for administration. In some embodiments, the anti-VISTA antibody or antigen-binding fragment and one or more other therapeutic agents are administered separately and can be administered in the same or different manners.

[0129] The method of administration of anti-VISTA antibodies or antigen-binding fragments and one or more other therapeutic agents independently includes but is not limited to intradermal, intramuscular, peritoneal, intravenous, subcutaneous, nasal, epidural and oral injection. The pharmaceutical composition can be administered by any convenient route, such as by infusion or bolus injection, absorbed by epithelial or mucocutaneous membranes (such as oral mucosa, rectal and intestinal mucosa, etc.), and can be co-administered with other bioactive agents. Therefore, the pharmaceutical composition containing the antibody or antigen-binding fragment of the present invention can be administered orally, rectally, parenterally, intracisternal, intravaginally, intraperitoneally, externally (such as by powder, ointment, drops or transdermal patch), orally or by oral or nasal spray.

[0130] The term "parenteral" as used herein refers to modes of administration including intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

[0131] Administration can be systemic or local. In addition, it may be necessary to introduce the antibodies of the present invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection can be assisted by connecting an intraventricular catheter to a reservoir (which can be an Ommaya reservoir). Pulmonary administration is also possible, for example, by using an inhaler or nebulizer, as well as using aerosolized preparations.

[0132] The anti-VISTA antibody or antigen-binding fragment and one or more other therapeutic agents can be independently administered topically to the area in need of treatment; this can be achieved by, but is not limited to, topical administration during surgery, such as in conjunction with a postoperative wound dressing, by injection, by catheter, by suppository, or by implantation, wherein the implant is a porous, non-porous, or gel-like material, including a membrane (e.g., a silicone rubber membrane) or fiber. In some embodiments, when administering proteins (including antibodies) of the invention, care must be taken to use materials that do not absorb the protein.

[0133] In some embodiments, the compositions of the invention comprise nucleic acids or polynucleotides encoding antibodies, which can be administered in vivo to promote expression of the encoded protein by constructing them into a suitable nucleic acid expression vector, which is then administered intracellularly, for example, by using retroviral vectors (see U.S. Pat. No. 4,980,286), or by direct injection, or by using microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or by coating with lipids or cell surface receptors or transfection reagents, or by linking to a homeobox peptide known to enter the nucleus (see, e.g., Joliot et al., 1991, Proc. Natl. Acad. Sci. USA 88: 1864-1868), etc. Alternatively, the nucleic acid can be introduced into the cell by homologous recombination and integrated into the host cell DNA for expression.

[0134] In some embodiments, the dosage of the anti-VISTA antibody administered to the patient is 0.01 mg / kg to 100 mg / kg of patient weight, or 0.1 mg / kg to 20 mg / kg of patient weight. After the initial dose, a second dose or multiple doses of the antibody or antigen-binding fragment may be subsequently administered, the dose being approximately the same as or less than the initial dose, wherein the subsequent doses may be separated by at least 1 to 3 days; or at least one week. The uptake and tissue penetration ability (e.g., into the brain) of the antibody can be enhanced by modifications such as lipidation, thereby reducing the dosage and frequency of administration of the antibody of the present invention.

[0135] Anti-VISTA antibodies are used to perform in vitro testing for methods of treating diseases, including administering the anti-VISTA antibodies or derivatives of the present invention, followed by in vivo testing of the desired therapeutic or preventive activity in an acceptable animal model, and finally administered to humans. Suitable animal models (including transgenic animals) are well known to those of ordinary skill in the art. For example, in vitro assays for demonstrating the therapeutic use of the anti-VISTA antibodies and antigen-binding fragments of the present invention include the effects of antibodies on cell lines or patient tissue samples. The effects of antibodies on cell lines and / or tissue samples can be detected using techniques known to those skilled in the art, such as the techniques disclosed in other parts of the present invention. According to the present invention, in vitro assays for determining whether specific antibodies are administered include in vitro cell culture experiments, in which patient tissue samples are cultured in culture and exposed to or otherwise administered with a compound, and the effects of such compounds on tissue samples are observed.

[0136] Various known delivery systems can be used to administer the antibodies or derivatives of the present invention or polynucleotides encoding the same, such as encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, 1987, J. Biol. Chem. 262: 4429-4432), construction of the nucleic acid as part of a retroviral or other vector, etc.

[0137] Combination therapy of anti-VISTA antibodies and anti-PD-L1 antibodies

[0138] Programmed death receptor-1 (PD-1) is a type I transmembrane glycoprotein with a molecular weight of approximately 55 kDa. PD-1 is an immunoinhibitory receptor expressed on activated T cells, B cells, and myeloid cells, and is a member of the CD28 immunoglobulin superfamily. PD-1's ligand, PD-L1, is also a type I transmembrane glycoprotein with a wide distribution: it is expressed on the surface of antigen-presenting cells such as B cells, T cells, dendritic cells, and macrophages, as well as in tumor tissues.

[0139] In some embodiments, the present invention provides use of an anti-VISTA antibody or antigen-binding fragment described herein in the preparation of a medicament for use in combination with an anti-PD-L1 antibody or antigen-binding fragment.

[0140] In some embodiments, the present invention provides use of the anti-VISTA antibodies or antigen-binding fragments and anti-PD-L1 antibodies or antigen-binding fragments described herein in the preparation of a medicament for treating a disease.

[0141] In some embodiments, the present invention provides use of an anti-VISTA antibody or antigen-binding fragment described herein in combination with an anti-PD-L1 antibody or antigen-binding fragment for treating a disease.

[0142] In some embodiments, the present invention provides a method for treating a disease, such as a method for preventing, treating, or ameliorating a T cell dysfunction disorder, comprising administering an effective dose of an anti-VISTA antibody or antigen-binding fragment and an anti-PD-L1 antibody or antigen-binding fragment described herein to a patient in need of treatment.

[0143] In some embodiments, the anti-VISTA antibody or antigen-binding fragment and the anti-PD-L1 antibody are administered simultaneously. When the anti-VISTA antibody or antigen-binding fragment and the anti-PD-L1 antibody or antigen-binding fragment are administered simultaneously, the anti-VISTA antibody or antigen-binding fragment and the anti-PD-L1 antibody or antigen-binding fragment can be administered in the same or different manners, or prepared as a composition of the anti-VISTA antibody or antigen-binding fragment and the anti-PD-L1 antibody or antigen-binding fragment for administration. In some embodiments, the anti-VISTA antibody or antigen-binding fragment and the anti-PD-L1 antibody or antigen-binding fragment are administered separately. In some embodiments, the anti-VISTA antibody or antigen-binding fragment is administered before the anti-PD-L1 antibody or antigen-binding fragment. In some embodiments, the anti-VISTA antibody or antigen-binding fragment is administered after the anti-PD-L1 antibody or antigen-binding fragment.

[0144] In some embodiments, the present invention provides a composition comprising an anti-VISTA antibody or antigen-binding fragment described herein and an anti-PD-L1 antibody or antigen-binding fragment.

[0145] In some embodiments, the present invention provides a method for preventing, treating, or ameliorating a T cell dysfunction disorder, comprising administering to a patient an effective dose of a composition comprising an anti-VISTA antibody or antigen-binding fragment and an anti-PD-L1 antibody or antigen-binding fragment described herein.

[0146] In some embodiments, the anti-PD-L1 antibody used in combination with the anti-VISTA antibody or antigen-binding fragment described herein is an anti-PD-L1 antibody or antigen-binding fragment described herein.

[0147] In some embodiments, the uses, methods, and compositions of the combined use of anti-VISTA antibodies or antigen-binding fragments of the present invention and anti-PD-L1 antibodies or antigen-binding fragments can also be combined with other treatment or prevention regimens, including the administration of one or more antibodies or antigen-binding fragments of the present invention, anti-PD-L1 antibodies or antigen-binding fragments, and one or more other therapeutic agents or methods. In some embodiments, other treatment regimens include, but are not limited to, radiotherapy, chemotherapy, hormone therapy, biologic therapy, and the like. For combination therapy, these therapeutic agents can be administered simultaneously or separately. When administered separately, these therapeutic agents can be administered in different orders.

[0148] In some embodiments, therapeutic antibodies that can be administered in conjunction with the methods, uses, or compositions of the present invention in combination with antibodies or antigen-binding fragments and anti-PD-L1 antibodies or antigen-binding fragments include, but are not limited to, anti-CD3 antibodies, anti-PD-1 antibodies, anti-PD-L2 antibodies, anti-TIM-3 antibodies, anti-LAG-3 antibodies, anti-OX40 antibodies, and anti-GITR antibodies, such as atezolizumab, avelumab, druvalumab, Envafolimab, nivolumab, pembrolizumab, tremelimumab, ipilimumab, and trastuzumab.

[0149] In some embodiments, angiogenesis inhibitors that can be administered with the methods, uses, or compositions combined with the antibodies or antigen-binding fragments and anti-PD-L1 antibodies or antigen-binding fragments of the present invention include, but are not limited to, angiostatin (a plasminogen fragment), anti-angiogenic antithrombin III, and ribozymes.

[0150] In some embodiments, anticancer agents that can be administered with the methods, uses, or compositions in combination with the antibodies or antigen-binding fragments of the present invention and anti-PD-L1 antibodies or antigen-binding fragments include, but are not limited to, 5-fluorouracil, acivicin, aldesleukin, hexamethylmelamine, aminoglutethimide, amsacrine, anastrozole, anthramycin, asparaginase, azacitidine, azatepa, azotocin, batimastat, bicalutamide, bleomycin sulfate, brequinar sodium, bropiridamine, busulfan, carboplatin, carmustine, carrubicin hydrochloride, carzelesin, cedifingol, chlorambucil, sirolimus, cisplatin, cladribine, cristatol mesylate, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin hydrochloride, decitabine, dextromaplatin, dezaguanine, dezaguanine mesylate. mesylate), diazaquin, docetaxel, doxorubicin, doxorubicin hydrochloride, droloxifene, droloxifene citrate, drolostanone propionate, dazomib, edatrexate, eflornithine hydrochloride, enloplatin, enprobamate, epiripridine, epirubicin hydrochloride, erbulazole, isorubicin hydrochloride, estramustine, estramustine sodium phosphate, etanidazole, etoposide, etoposide phosphate, fazarabine, fenretinide, floxuridine, fludarabine phosphate, fluorouracil, flucitabine, fosquadone, fostramecin sodium, gemcitabine, gemcitabine hydrochloride, hydroxyurea, idarubicin hydrochloride, ifosfamide, imofosine, interleukin II (including recombinant interleukin II), interferon alfa-2a, interferon alfa-2b, interferon alfa-m, interferon alfa-n3, interferon beta-Ia, interferon gamma-I b. Iproplatin, irinotecan hydrochloride, lanreotide acetate, letrozole, leuprorelin acetate, lirazolam hydrochloride, lometrexol sodium, lomustine, losoxantrone hydrochloride, masorol, nitrogen mustard hydrochloride, megestrol acetate, ethinyl estradiol acetate, melphalan, menolide, mercaptopurine, methotrexate, methotrexate sodium, chlorpheniraminedaptomycin, metodepa, mitomycin, mitospe, mitotane, mitoxantrone hydrochloride, mycophenolic acid, nocodazole, ormaplatin, paclitaxel, pegaspargase, porfromycin, prednimustine, procarbazine hydrochloride, puromycin, roglulimine, safinol hydrochloride, semustine, semporfin sodium, sparmycin, spiromustine, spiroplatin, streptozocin, streptozotocin, sulfaquinoxaline, terisomycin, tegafur, tiloxantrone hydrochloride, temoporfin, teniposide, tiroxilon, Testolactone, thiamipurine, thioguanine, thiotepa, thiazofurine, tirapazamine, topotecan, trimetrexate, trimetrexate glucuronide, triptorelin, uramustine, uredepa, vapreotide, verteporfin, vinblastine sulfate, vincristine sulfate, vindesine, vindesine sulfate, vindropridine sulfate, vinsorbine sulfate, vinorelbine tartrate, vinprodine sulfate, vinblastine sulfate, vorazole, zeniplatin, fenstatin and zorubicin hydrochloride, etc.

[0151] Pharmaceutical composition

[0152] The present invention also provides a pharmaceutical composition. Such a composition comprises an effective dose of an anti-VISTA antibody or antigen-binding fragment, one or more other therapeutic agents, and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition comprises 0.1%-90% of an anti-VISTA antibody or antigen-binding fragment.

[0153] In some embodiments, the term "pharmaceutically acceptable" refers to substances approved by a government regulatory agency or listed in a recognized pharmacopoeia for use in animals, particularly humans. In addition, "pharmaceutically acceptable carrier" generally refers to any type of non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary agent.

[0154] The term "carrier" refers to a diluent, adjuvant, excipient or vehicle that can be administered to a patient together with the active ingredient. This type of pharmaceutical carrier can be a sterile liquid, such as water and oil, including oils of petroleum, animal, plant or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. When the pharmaceutical composition is administered intravenously, water is a preferred carrier. Saline solutions and aqueous glucose solutions and glycerol solutions can also be used as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, skimmed milk powder, glycerol, propylene, ethylene glycol, water, ethanol, etc. If necessary, the composition can also contain a small amount of wetting agent or emulsifier, or pH buffers such as acetate, citrate or phosphate. Antimicrobial agents such as benzyl alcohol or methyl parabens, antioxidants such as ascorbic acid or sodium bisulfite, chelating agents such as ethylenediaminetetraacetic acid, and agents for regulating tonicity such as sodium chloride or dextrose are also contemplated. These compositions can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained-release formulations, and the like. The compositions can be formulated as suppositories using conventional binders and carriers such as triglycerides. Oral formulations can include standard carriers such as pharmaceutical grade mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. Examples of suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences by EW Martin, which is incorporated herein by reference. Such compositions will contain a clinically effective dose of the antibody or antigen-binding fragment, preferably in purified form, together with an appropriate amount of carrier to provide a dosage form suitable for the patient. The formulation should be suitable for the mode of administration. The parent formulation can be packaged in ampoules, disposable syringes, or multidose vials made of glass or plastic.

[0155] In some embodiments, the composition is formulated into a pharmaceutical composition suitable for intravenous injection in human body according to conventional steps. The composition for intravenous administration is generally a solution in a sterile isotonic aqueous buffer. The composition may also include a solubilizing agent and a local anesthetic such as lidocaine to relieve pain at the injection site. Generally speaking, the active ingredient is supplied alone or mixed together in a unit dose form, such as in a sealed container (such as an ampoule or a pouch) that indicates the amount of active agent in the form of a dry lyophilized powder or anhydrous concentrate. In the case of administering the composition by infusion, the composition can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. In the case of administering the composition by injection, an ampoule of sterile water for injection or saline can be used so that the active ingredient can be mixed before administration.

[0156] The compounds of the present invention can be formulated into neutral or salt forms. Pharmaceutically acceptable salts include salts derived from anions such as hydrochloric acid, phosphoric acid, acetic acid, oxalic acid, tartaric acid, and the like, and salts derived from cations such as sodium, potassium, ammonium, calcium, ferric hydroxide, isopropylamine, triethylamine, 2-ethylaminoethanol, histidine, procaine, and the like.

[0157] "About" refers to the normal error range of the corresponding numerical value that is easily known to those skilled in the relevant art. In some embodiments, "about" mentioned herein refers to the described numerical value and its ±10%, ±5% or ±1% range.

[0158] “EC 50 "Concentration for 50% of maximal effect, EC 50 ) refers to the concentration that can cause 50% of the maximum effect.

[0159] In the present invention, the "parent Fc region" can be a naturally occurring Fc region, and the gene encoding the Fc region can be from humans, mice, rabbits, camels, monkeys, preferably humans and mice; for example, the parent Fc region is the Fc region in SEQ ID NO: 10, SEQ ID NO: 12 or SEQ ID NO: 13.

[0160] The following is a detailed description of the technical solution of the present invention, which does not limit the scope of protection of the present invention. Non-essential modifications or adjustments made by others based on the concept of the present invention still fall within the scope of protection of the present invention.

[0161] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0162] Example 1 Antibody Preparation Method

[0163] The antibodies prepared in this example include anti-VISTA antibodies and anti-PD-L1 antibodies. The amino acid sequences and nucleic acid sequences related to the antibodies are shown in Tables 1 to 6.

[0164] The amino acid sequences of the antibody's heavy and light chains are optimized according to the codon preferences of the host cell to obtain the DNA sequences of the heavy and light chains. To facilitate expression in the host cell, a signal peptide can be added to the N-terminus of the heavy and light chains.

[0165] The optimized and synthesized nucleic acid sequences were cloned into vectors (e.g., pCDNA3.1, V79020 from Invitrogen). Large quantities of plasmids were then extracted and transiently transfected into HEK293F cells at a 1:1 molar ratio of heavy and light chains. Using antibody P48-6-K as an example, the heavy chain nucleic acid sequence (positions 58-1407 of SEQ ID NO:17) and the light chain nucleic acid sequence (positions 61-702 of SEQ ID NO:18) were cloned into the expression vectors using enzyme digestion. The amino acid sequence of the heavy chain signal peptide is SEQ ID NO:15, and the amino acid sequence of the light chain signal peptide is SEQ ID NO:16. Taking the anti-PD-1 antibody L1-R2-4-71 (sequence from patent application CN114057877A) as an example, the heavy chain nucleic acid sequence (the heavy chain variable region nucleotide sequence is shown in SEQ ID NO: 21, positions 58-411) and the light chain nucleic acid sequence (the light chain variable region nucleotide sequence is shown in SEQ ID NO: 22, positions 67-387) are cloned into the expression vector by enzyme digestion; a signal peptide sequence is added, wherein the amino acid sequence of the heavy chain signal peptide is SEQ ID NO: 15, and the amino acid sequence of the light chain signal peptide is amino acids 1-22 of SEQ ID NO: 20. The positive reference antibody VSTB112 is an anti-VISTA antibody, and its preparation method is similar to the above (sequence is shown in patent application CN107922497A). After cell expression, the culture medium is purified by immobilized metal affinity chromatography (IMAC) using a Protein A column (GE Healthcare). The purity of the purified antibody protein is >95%.

[0166] Gel electrophoresis of the purified antibodies revealed that the P48-6-K and P48-6-T antibodies were single substances, with molecular weights consistent with theoretical values. Sequencing of the purified antibodies confirmed the predicted sequence. The purified antibodies were used for affinity testing and bioactivity characterization.

[0167] Table 1 Composition of antibodies

[0168] Table 2 CDR regions of anti-VISTA antibodies

[0169] Table 3 Variable and constant regions of anti-VISTA antibodies

[0170] Table 4 Heavy and light chains of anti-VISTA antibodies (the Fc region of the heavy chain is single underlined)

[0171] Table 5 Anti-VISTA Antibody Related Nucleic Acid Sequences (Signal Peptide Nucleic Acid Sequences are Double Underlined)

[0172] Table 6 Amino acid and nucleotide sequence of anti-PD-L1 antibody L1-R2-4-71 (double underlined is the signal peptide amino acid sequence, single underlined is the constant region sequence)

[0173] Example 2 Determination of Antibody Affinity

[0174] The affinity constant of the antibody was determined using a Biacore T200 surface plasmon resonance instrument. The main experimental process was as follows: Protein A chip was used for detection, 100nM antibody (P48-6-K, P48-6-T, VSTB112) dilution was passed through the experimental flow path (Fc2, Fc4) at a flow rate of 10μl / min, and the capture was about 560RU for 20s; then the flow rate was adjusted to 30μl / min, and different concentrations (0nM, 1.23nM, 3.7nM, 11.1nM, 33.3nM, 100nM) of VISTA-His (Acro, B75-H52H0) dilution (the dilution solvent was water) were sequentially introduced, and passed through the experimental flow path (Fc2, Fc4) and reference flow path (Fc1, Fc3) surfaces at the same time, with a binding time of 120s and a dissociation time of 300s. Finally, Glycine 1.5 The chip was regenerated and entered the next cycle; the experimental results were analyzed using the data analysis software Evaluation Software 3.1. The sensor signal collected from the sample experimental flow path was double-deducted by the reference flow path and the sample blank, and the kinetic "1:1" model was selected for fitting to obtain the kinetic parameters (Kon (Ka): association rate constant; Koff (Kd): dissociation rate constant; K D : association-dissociation equilibrium constant).

[0175] 1) As shown in Table 7, the affinity of antibody VSTB112 and the antibody of the present invention P48-6-K to VISTA-His is comparable.

[0176] Table 7 Affinity constants of antibody P48-6-K binding to VISTA-His

[0177] 2) As shown in Table 8, compared with the antibody VSTB112, the antibody P48-6-T of the present invention has better affinity with VISTA-His.

[0178] Table 8 Affinity constants of antibody P48-6-T binding to VISTA-His

[0179] Example 3 Detection of Antibody Binding to VISTA of Different Species

[0180] 100 μL, 1 μg / ml VISTA-Fc (human, cynomolgus monkey, mouse species, Sino biological Inc) was coated on the plate. The starting concentration of the anti-VISTA antibody was 2 μg / mL, and the dilution was performed in a 2-fold serial dilution (the dilution solvent was PBS buffer) and placed in a refrigerator at 4°C overnight. PBST (PBS + 0.05% Tween, 1 liter PBS contains NaCl 8.0 g, Na2HPO4 0.9 g, KH2PO4 0.156 g, KCl 0.125 g, pH The sections were washed three times (7.2-7.4), blocked with 5% BSA (bovine serum albumin) at room temperature for 2 h, and washed four times with PBST; incubated with 2 μg / mL antibody at room temperature for 1.5 h, and washed four times with PBST; after washing, incubated with goat anti-human kappa light chain-peroxidase antibody (SIGMA, Catalog No. A7164) for 0.5 h; washed six times with PBST, added with 100 μL tetramethylbenzidine (TMB), incubated at 37°C for 5 min, and terminated by adding 50 μL 0.1 M sulfuric acid; and the absorbance at 450 nm was read with a microplate reader.

[0181] As shown in Table 9, antibodies VSTB112, P48-6-K, and P48-6-T bind to human and cynomolgus monkey VISTA, but do not bind to mouse VISTA.

[0182] Table 9 EC of antibodies binding to VISTA-FC 50 (μg / mL)

[0183] Note: NA means no binding.

[0184] Example 4 Detection of the binding ability of antibodies to cells expressing VISTA

[0185] CHO-VISTA cells were prepared as follows: human VISTA full-length amino acid sequence (from UniProtKB-Q9H7M9): “MGVPTALEAGSWRWGSLLFALFLAASLGPVAAFKVATPYSLYVCPEGQNVTLTCRLLGPVDKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLESASDHHGNFSITMRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVVYPSSSQDSENITAAALATGACIVGILCLPLILLLVYK QRQAASNRRAQELVRMDSNIQGIENPGFEASPPAQGIPEAKVRHPLSYVAQRQPSESGRHLLSEPSTPLSPPGPGDVFFPSLDPVPDSPNFEVI” (SEQ ID NO: 23); The nucleic acid sequence corresponding to NO:23 was constructed, and HindIII and EcoRI restriction sites were added at both ends of the sequence. The construct was then inserted into the pcDNA3.1 expression vector (Invitrogen, V79020) and then transfected into CHO cells by electroporation. The electroporation conditions were: voltage 300V, time 17 milliseconds, 4mm electroporation cup, and 50μM MSX (methionine iminosulfone) was added after 48h to screen positive cells. FACS (flow cytometry) detection was used to screen high-expressing cell lines and collect cells. After washing with PBS once, 3μg / ml antibody VSTB112 was added, incubated at 4°C for 1h, washed twice with PBS, and then 100μl 1:500 diluted goat anti-human IgG-Fc PE fluorescent secondary antibody (catalog number 12-4998-82, eBioscience) was added. After incubation at 4°C for 1h, washed twice with PBS, and analyzed using a C6 flow cytometer. The resulting cells were named CHO-VISTA cells.

[0186] The starting concentration of anti-VISTA antibody was 5 μg / mL, and the dilution was 2-fold, with 100 μL of antibody diluent and 100 μL of 5×10 5 CHO-VISTA cells were mixed evenly and incubated at 4°C for 30 min. After washing the cells twice with PBS, goat anti-human IgG-Fc PE fluorescent secondary antibody (1:1000 diluted in PBS) was added and incubated at 4°C for 30 min. The cells were washed twice with PBS and resuspended in 200 μL PBS (Gibco). The fluorescence intensity of the second channel was measured using a flow cytometer CytoFLEX.

[0187] The results showed that the EC binding of antibodies VSTB112, P48-6-K and P48-6-T to VISTA-CHO cells 50 The values ​​were 1.52 μg / mL, 1.01 μg / mL and 1.22 μg / mL respectively.

[0188] Example 5 Antibody Blocks Binding of VISTA to Ligand VSIG-3

[0189] The plate was coated with 10 μg / mL VSIG-3 (Recombinant Human VSIG3 Fc Chimera Protein, R&D, Catalog No. 9229-VS-050) and incubated at 4°C overnight; washed three times with PBST, blocked with 5% BSA at room temperature for 2 hours, and washed four times with PBST; 10 μg / mL biotin-labeled VISTA (Acro, Catalog No. B75-H82F3) was mixed with antibody P48-6-K dilution (starting at 15 μg / mL, with a 2-fold serial dilution) and added to the plate, incubated at room temperature for 1.5 hours, and washed four times with PBST; after washing, the plate was incubated with streptavidin-labeled horseradish peroxidase (Streptavidin-HRP) for 0.5 hours; washed six times with PBST, 100 μL tetramethylbenzidine (TMB) was added, incubated at 37°C for 5 minutes, and terminated by adding 50 μL 0.1 M sulfuric acid; the absorbance at 450 nm was read on a microplate reader.

[0190] As shown in FIG2 , the antibody P48-6-K of the present invention can block the binding of VSIG-3 to VISTA in a concentration-dependent manner.

[0191] Example 6 Detection of cytokines

[0192] Peripheral blood was collected from healthy adults and diluted 1:1 with normal saline (Sichuan Kelun Pharmaceutical Co., Ltd.). An equal volume of human peripheral blood lymphocyte separation solution (Dakoway Biotechnology Co., Ltd., Dayou Pharmaceutical Co., Ltd.) was slowly added. ) and centrifuged at 800 g for 30 min. The middle white layer was aspirated and washed twice with PBS. The cells were resuspended in RPMI-1640 medium (Gibco) containing 10% FBS (fetal bovine serum, Gibco) and the cells were counted. The concentration of PBMC cells (peripheral blood mononuclear cells) was adjusted to 10 6 pieces / mL.

[0193] Anti-VISTA antibody was diluted in RPMI-1640 medium (initial concentration was 6 μg / mL, 3-fold serial dilution) and added to a U-shaped 96-well plate, 100 μL per well, with two parallel wells; 100 μL of PBMC cell solution was added and mixed evenly; the plate was cultured in a 37°C, 5% carbon dioxide incubator for approximately 18 h.

[0194] IP-10 (interferon-inducible protein 10) was detected using a human CXCL10 / IP-10 ELISA kit (R&D Systems, cat. no. DY266). The detection steps are as follows: IP-10 capture antibody coated plate at 4°C overnight, washed 3 times with PBST, blocked with 1% BSA at room temperature for 2 hours, and washed 4 times with PBST; U-shaped 96-well plate (containing PBMC cells and antibodies) was centrifuged at 2000rpm for 5 minutes, 100 μL of supernatant was added to the ELISA plate, appropriate concentration gradient standards were prepared, incubated at room temperature for 1.5 hours, washed 4 times with PBST, 100 μL of biotin-labeled IP-10 detection antibody solution was added, incubated at room temperature for 1.5 hours, and washed 4 times with PBST; 100 μL of streptavidin-labeled horseradish peroxidase solution was added, incubated at room temperature for 0.5 hours, and washed 6 times with PBST; 100 μL of tetramethylbenzidine (TMB) was added, incubated at 37°C for 5 minutes, and then 50 μL of 0.1M sulfuric acid was added to terminate the reaction; the absorbance value at 450 nm was read with a microplate reader.

[0195] The results showed that the antibodies VSTB112 and P48-6-T promoted PBMC cells to secrete the EC corresponding to the chemokine IP-10. 50 The values ​​were 0.0052μg / ml and 0.0054μg / ml respectively. The activities of the two in promoting PBMC cells to secrete chemokine IP-10 were basically similar, and the secreted chemokine IP-10 could chemotactically activate monocytes and T cells.

[0196] Example 7 T cell proliferation assay

[0197] The PBMC cell isolation method was the same as in Example 6, using CD3 + T cell isolation kit (Mojosort™ Human CD3 T cell Isolation Kit, Biolegend) was used to separate CD3 positive T cells (i.e. CD3 + The day before the experiment, 1 μg / ml anti-CD3 antibody (Recombinant Anti-CD3 mAb, novoprotein, GMP-A018) and 10 μg / ml antibodies VSTB112, P48-6-K, and isotype control IgG1 (HG1K, Sino Biological) were co-plated and incubated overnight at 4°C. After washing twice with PBS, 100,000 cells / well of CD3 were added. + T cells, volume 100 μL, were cultured for 3 days and cell proliferation was detected using CellTiter (CellTiter-Glo™, Promega).

[0198] As shown in Figure 3, when the antibody P48-6-K and anti-CD3 antibody are co-coated, they can promote T cell proliferation and thus enhance immune capacity.

[0199] Example 8 Antitumor Effect

[0200] Experimental mice: Female BALBc-hVISTA mice (VISTA humanized mice, sourced from Jiangsu Jicui Yaokang Biotechnology Co., Ltd.). Experimental cells: CT26.WT (colorectal cancer) cells (Jicui Yaokang) in the logarithmic growth phase were collected, culture medium removed, washed, and then inoculated; inoculum size: 5×10 5 Cells / 100 μL / mouse; Inoculation site: right upper thigh on the back of the mouse. Grouping and dosing: Three days after tumor cell inoculation, mice were randomly divided into five groups based on body weight, with 10 mice in each group. The day of inoculation was defined as Day 0, and dosing began on the day of grouping according to the experimental protocol. The dosage and administration method are shown in Table 10. The dosing volume was calculated as 10 μL / g.

[0201] After cell inoculation, the effect of the tumor on the normal behavior of the animals was routinely monitored weekly. Specific contents: activity of the experimental animals, food and water intake, weight gain or loss, eye, fur and other abnormalities. Clinical symptoms observed during the experiment were recorded in the original data. After the start of administration, the body weight was weighed twice and the tumor volume was measured twice in the first week; thereafter, the body weight was weighed three times and the tumor volume was measured three times per week. Tumor volume was calculated as follows: tumor volume (mm 3 ) = 0.5 × tumor long diameter × tumor short diameter 2 , tumor volume inhibition rate TGITv = (1-average tumor volume of the treatment group / average tumor volume of the control group) × 100%, tumor weight inhibition rate TGITw = (1-average tumor weight of the treatment group / average tumor weight of the control group) × 100%.

[0202] Table 10 Experimental design table

[0203] The results of tumor volume inhibition are shown in Figures 4A and 4B and Tables 11A and 11B. Compared to the G1 group, antibody P48-6-T significantly inhibited tumor growth on day 30 post-inoculation. In particular, the combined administration of antibody P48-6-T of the present invention and antibody L1-R2-4-71 further inhibited tumor growth. As shown in Figure 5, there were no significant differences in body weight among the mice in the various groups.

[0204] Table 11A Tumor volume inhibition rate on day 30

[0205] Table 11B Tumor re-inhibition rate on day 30

Claims

1. A composition comprising an anti-VISTA antibody or antigen-binding fragment and one or more other therapeutic agents, wherein: The anti-VISTA antibody or antigen-binding fragment comprises one or more of HCDR1 as shown in SEQ ID NO: 1, HCDR2 as shown in SEQ ID NO: 2, HCDR3 as shown in SEQ ID NO: 3, LCDR1 as shown in SEQ ID NO: 4, LCDR2 as shown in SEQ ID NO: 5, and LCDR3 as shown in SEQ ID NO: 6; the other therapeutic agent is an angiogenesis inhibitor, an anticancer agent, a targeted drug, or a therapeutic antibody; for example, the other therapeutic agent is selected from antibodies or antigen-binding fragments or antibody-drug conjugates targeting the following targets: PD-L1, PD-1, and CD3.

2. Use of an anti-VISTA antibody or antigen-binding fragment in the preparation of a medicament for use in combination with one or more other therapeutic agents, comprising administering the anti-VISTA antibody or antigen-binding fragment and the one or more other therapeutic agents to a patient in need thereof; wherein, The anti-VISTA antibody or antigen-binding fragment comprises one or more of HCDR1 as shown in SEQ ID NO: 1, HCDR2 as shown in SEQ ID NO: 2, HCDR3 as shown in SEQ ID NO: 3, LCDR1 as shown in SEQ ID NO: 4, LCDR2 as shown in SEQ ID NO: 5, and LCDR3 as shown in SEQ ID NO: 6; the other therapeutic agent is an angiogenesis inhibitor, an anticancer agent, a targeted drug, or a therapeutic antibody; for example, the other therapeutic agent is selected from antibodies or antigen-binding fragments or antibody-drug conjugates targeting the following targets: PD-L1, PD-1, and CD3.

3. Use of an anti-VISTA antibody or antigen-binding fragment in combination with one or more other therapeutic agents, comprising administering an anti-VISTA antibody or antigen-binding fragment and one or more other therapeutic agents to a patient in need thereof; wherein, The anti-VISTA antibody or antigen-binding fragment comprises one or more of HCDR1 as shown in SEQ ID NO: 1, HCDR2 as shown in SEQ ID NO: 2, HCDR3 as shown in SEQ ID NO: 3, LCDR1 as shown in SEQ ID NO: 4, LCDR2 as shown in SEQ ID NO: 5, and LCDR3 as shown in SEQ ID NO: 6; the other therapeutic agent is an angiogenesis inhibitor, an anticancer agent, a targeted drug, or a therapeutic antibody; for example, the other therapeutic agent is selected from antibodies or antigen-binding fragments or antibody-drug conjugates targeting the following targets: PD-L1, PD-1, and CD3.

4. Use of an anti-VISTA antibody or antigen-binding fragment and one or more other therapeutic agents in the preparation of a medicament for treating a disease, wherein: The anti-VISTA antibody or antigen-binding fragment comprises one or more of HCDR1 as shown in SEQ ID NO: 1, HCDR2 as shown in SEQ ID NO: 2, HCDR3 as shown in SEQ ID NO: 3, LCDR1 as shown in SEQ ID NO: 4, LCDR2 as shown in SEQ ID NO: 5, and LCDR3 as shown in SEQ ID NO: 6; the other therapeutic agent is an angiogenesis inhibitor, an anticancer agent, a targeted drug, or a therapeutic antibody; for example, the other therapeutic agent is selected from antibodies or antigen-binding fragments or antibody-drug conjugates targeting the following targets: PD-L1, PD-1, and CD3.

5. A method for preventing, treating, or ameliorating a disease, comprising administering an anti-VISTA antibody or antigen-binding fragment and one or more other therapeutic agents to a patient in need thereof; wherein, The anti-VISTA antibody or antigen-binding fragment comprises one or more of HCDR1 as shown in SEQ ID NO: 1, HCDR2 as shown in SEQ ID NO: 2, HCDR3 as shown in SEQ ID NO: 3, LCDR1 as shown in SEQ ID NO: 4, LCDR2 as shown in SEQ ID NO: 5, and LCDR3 as shown in SEQ ID NO: 6; the other therapeutic agent is an angiogenesis inhibitor, an anticancer agent, a targeted drug, or a therapeutic antibody; for example, the other therapeutic agent is selected from antibodies or antigen-binding fragments or antibody-drug conjugates targeting the following targets: PD-L1, PD-1, and CD3.

6. The composition, use or method according to any one of claims 1 to 5, wherein The anti-VISTA antibody or antigen-binding fragment comprises HCDR1 as shown in SEQ ID NO: 1, HCDR2 as shown in SEQ ID NO: 2, and HCDR3 as shown in SEQ ID NO: 3; and / or The anti-VISTA antibody or antigen-binding fragment comprises LCDR1 as shown in SEQ ID NO: 4, LCDR2 as shown in SEQ ID NO: 5, and LCDR3 as shown in SEQ ID NO: 6; For example, the antibody or antigen-binding fragment comprises HCDR1 as shown in SEQ ID NO: 1, HCDR2 as shown in SEQ ID NO: 2, HCDR3 as shown in SEQ ID NO: 3, LCDR1 as shown in SEQ ID NO: 4, LCDR2 as shown in SEQ ID NO: 5 and LCDR3 as shown in SEQ ID NO:

6.

7. The composition, use or method according to any one of claims 1 to 6, wherein (1) the anti-VISTA antibody or antigen-binding fragment comprises a heavy chain variable region, wherein the heavy chain variable region comprises the sequence shown in SEQ ID NO: 7 or 8, or a sequence having at least 80% identity to the sequence shown in SEQ ID NO: 7 or 8, or an amino acid sequence having one or more conservative amino acid substitutions compared to the sequence shown in SEQ ID NO: 7 or 8, or consists of the same; and / or The anti-VISTA antibody or antigen-binding fragment comprises a light chain variable region, wherein the light chain variable region comprises, or consists of, the sequence shown in SEQ ID NO: 9, or a sequence having at least 80% identity to the sequence shown in SEQ ID NO: 9, or an amino acid sequence having one or more conservative amino acid substitutions compared to the sequence shown in SEQ ID NO: 9; or (2) the amino acid sequence of the heavy chain variable region of the anti-VISTA antibody or antigen-binding fragment is as shown in SEQ ID NO: 7, and the amino acid sequence of the light chain variable region is as shown in SEQ ID NO: 9; or The amino acid sequence of the heavy chain variable region of the anti-VISTA antibody or antigen-binding fragment is shown in SEQ ID NO: 8, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 9; The anti-VISTA antibody or antigen-binding fragment optionally further comprises a heavy chain constant region, the heavy chain constant region comprising an amino acid sequence as shown in SEQ ID NO: 10, or a sequence having at least 80% identity with the sequence shown in SEQ ID NO: 10, or an amino acid sequence having one or more conservative amino acid substitutions compared to the sequence shown in SEQ ID NO: 10, or consisting thereof; and / or a light chain constant region, the light chain constant region comprising an amino acid sequence as shown in SEQ ID NO: 11, or a sequence having at least 80% identity with the sequence shown in SEQ ID NO: 11, or an amino acid sequence having one or more conservative amino acid substitutions compared to the sequence shown in SEQ ID NO:

11. or (3) the amino acid sequence of the anti-VISTA antibody heavy chain is shown in SEQ ID NO: 12, and the amino acid sequence of the anti-VISTA antibody light chain is shown in SEQ ID NO: 14; or The amino acid sequence of the anti-VISTA antibody heavy chain is shown in SEQ ID NO: 13, and the amino acid sequence of the anti-VISTA antibody light chain is shown in SEQ ID NO:

14.

8. The composition, use or method according to any one of claims 1 to 7, wherein The other therapeutic agent is an anti-CD3 antibody or an anti-PD-L1 antibody or antigen-binding fragment; for example, the anti-PD-L1 antibody is atezolizumab, avelumab, durvalumab, or envolimab; Alternatively, the anti-PD-L1 antibody or antigen-binding fragment comprises HCDR1, HCDR2, and HCDR3 with amino acid sequences as shown in SEQ ID NOs: 24 to 26, respectively, and LCDR1, LCDR2, and LCDR3 with amino acid sequences as shown in SEQ ID NOs: 27 to 29, respectively.

9. The composition, use or method according to claim 8, wherein The anti-PD-L1 antibody or antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence as shown in positions 20-137 of SEQ ID NO: 19, or a sequence having at least 80% identity with positions 20-137 of SEQ ID NO: 19, or an amino acid sequence having one or more conservative amino acid substitutions with positions 20-137 of SEQ ID NO: 19; and The anti-PD-L1 antibody or antigen-binding fragment comprises a light chain variable region, the amino acid sequence of which is shown as positions 23-129 of SEQ ID NO: 20, or a sequence having at least 80% identity with positions 23-129 of SEQ ID NO: 20, or an amino acid sequence having one or more conservative amino acid substitutions with positions 23-129 of SEQ ID NO:

20.

10. The composition, use or method of claim 8, wherein The heavy chain amino acid sequence of the anti-PD-L1 antibody is shown at positions 20-467 of SEQ ID NO: 19; the light chain amino acid sequence of the anti-PD-L1 antibody is shown at positions 23-236 of SEQ ID NO:

20.

11. The composition, use or method of any one of claims 1 to 9, wherein the anti-VISTA antibody or antigen-binding fragment and the other therapeutic agent are administered separately or simultaneously.

12. Use of the composition according to any one of claims 1 to 11, wherein the use is: Use in the preparation of a medicament for preventing, treating or improving T cell dysfunction; or The use according to any one of claims 1 to 11, wherein The use is to prevent, treat or improve T cell dysfunction; or The method according to any one of claims 1 to 11, wherein the disease is a T cell dysfunction disorder.

13. The use, application or method according to claim 12, wherein: The T cell dysfunction disorder includes tumors, cancer or infection; For example, the cancer or tumor is selected from breast cancer, digestive tract cancer / gastrointestinal cancer, endocrine cancer, neuroendocrine cancer, eye cancer, Eye cancer, genitourinary cancer, germ cell cancer, gynecological cancer, head and neck cancer, hematological / blood cancer, musculoskeletal cancer, neurological cancer, respiratory / thoracic cancer, bladder cancer, colon cancer, rectal cancer, colorectal cancer, lung cancer, endometrial cancer, kidney cancer, pancreatic cancer, liver cancer, stomach cancer, testicular cancer, esophageal cancer, prostate cancer, brain cancer, cervical cancer, ovarian cancer and thyroid cancer, leukemia, lymphoma, myelodysplastic syndrome or myeloma.